Follow my blog with Bloglovin The Food and Drug Administration has told the makers of Synthroid, the third most frequently prescribed drug in the U.S., that the medicine has a “history of problems” and cannot be recognized as “safe and effective.”The agency’s statements raise the possibility that the 40-year-old drug, which has never been officially Read more about Abbott’s Synthroid Faces Removal[…]
AltaRex Corp. has obtained an exclusive worldwide license for a family of four U.S issued patents and foreign counterparts from the Alberta Research Council, Inc. (ARC) in Edmonton, Alberta. These additions to the Company’s intellectual property portfolio provide AltaRex with a strong foundation for developing novel treatments in the area of autoimmune/inflammatory disease, such as Read more about AltaRex Licenses U.S. Issued Patents[…]
Scios Inc. has announced its entry into a research collaboration with Medtronic, Inc. to study the effects of Scios’ investigational agent Natrecor (nesiritide) in combination with Medtronic’s heart failure devices and implantable infusion systems. “We are excited to establish this collaboration as both Scios and Medtronic have a shared commitment to the diagnosis and management Read more about Scios And Medtronic To Develop Heart Failure Treatment[…]
Cell Pathways, Inc. and Bristol-Myers Squibb Company plan to cooperate in supporting a clinical trial to study the combination of Aptosyn (exisulind) and TAXOL (paclitaxel) plus Paraplatin (carboplatin) as a first-line treatment for patients with advanced non- small cell lung cancer (NSCLC). This Phase I/II study is designed to evaluate escalating doses of Aptosyn in Read more about Cell Pathways And Squibb Agree Joint Study[…]
Idun Pharmaceuticals, Inc. has extended their worldwide research and development agreement with Abbott Laboratories focusing on the discovery and development of products to treat people with cancer. Under this agreement, Abbott and Idun will continue their collaboration to discover drugs that regulate the activity of specific proteins involved in the cell pathways leading to programmed Read more about Idun And Abbott Extend Partnership Agreement[…]
Interneuron Pharmaceuticals, Inc. has exercised its option and entered into an agreement to license IP 501, an orally-administered anti-fibrotic purified phospholipid compound in Phase 3 development for the treatment and prevention of liver diseases, including alcohol and Hepatitis C-induced cirrhosis. The license agreement gives Interneuron rights to develop and commercialise the drug in several major Read more about Interneuron Licenses Treatment For Liver Disease[…]
Neurogenetics, Inc. has reported that a study published in the September issue of Neuron links a new mechanism-based therapeutic approach, licensed by the Company from Massachusetts General Hospital (MGH), to Alzheimer’s disease (AD). Researchers from the MGH Genetics and Aging Unit report that they have discovered a key link between two cellular abnormalities associated with Read more about Study Reports Link Between Alzheimer’s Cellular Abnormalities[…]
Novazyme Pharmaceuticals, Inc. has received formal notification from the Office of Orphan Products Development at the FDA that its proprietary, highly phosphorylated enzyme replacement therapy for the treatment of Pompe Disease has been granted orphan drug status. This notification from the FDA represents the first official validation of Novazyme‘s core phosphorylation technology platform with which Read more about Pompe Disease Therapy Receives Orphan Designation[…]
Coulter Pharmaceutical, Inc. has entered into a license and research agreement with Yissum, the technology transfer company of Hebrew University, for technology, know-how and worldwide intellectual property rights relating to a novel approach to treating rheumatoid arthritis (RA). This new approach involves reducing RA joint inflammation by targeting the synovial cells responsible for infiltrating and Read more about Coulter Acquires Rights To Novel Technology[…]
Corixa Corporation has been awarded a $2.3 million Challenge Grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop a new candidate vaccine for the treatment of tuberculosis. As a result, Corixa will conduct preclinical and clinical testing of a new candidate vaccine produced using M. tuberculosis proteins, combined with formulations developed Read more about Corixa Receives Grant To Develop Tuberculosis Vaccine[…]
Administration: Oral
Prime Constituent: Methandrostenolone
Producer: Dragon Pharmaceutical
Pack: 20 x 100 pastilles (20 mg/pill)
Price: 20 x $32.00
Injectable Anabolic Steroid
Basal Substance: Boldenone Undecylenate, Testosterone Enanthate
Producer: Dragon Pharma LLC
Package: 1 X 10 mL vial (400 mg/mL)
Administration: Injection
Main Component: Trenbolone Hexahydrobenzylcarbonate
Produced by: Dragon Pharmaceuticals
Package: 10 x 10 mL vial (100 mg/mL)
Price: 10 x $69.00
Administration: Injection
Prime Chemical Name: Testosterone Propionate
Produced by: Dragon Pharma LLC
Pack: 10 x 10 mL vial (100 mg/mL)
Price: 10 x $30.00
Administration: Injection
Principal Component: Testosterone Blend
Producer: Dragon Pharma
Pack: 30 x 10 mL vial (350 mg/mL)
Price: 30 x $32.00
Injectable Anabolic Steroid
Active Substance: Drostanolone Enanthate, Testosterone Enanthate, Trenbolone Enanthate
Made by: Dragon Pharma Labs
Unit: 1 X 10 ml (300 mg/ml)
Administration: Injection
Main Substance: Methenolone Enanthate
Producer: Dragon Pharma LLC
Pack: 30 x 10 mL vial (100 mg/mL)
Price: 30 x $55.00
Oral Steroid for Muscle Growth
Primary Ingredient: Oxandrolone
Manufacturer: Dragon Pharma LLC
100 pastilles (50 mg/tab)
Base Ingredient: Nandrolone Decanoate
Producer: Dragon Pharmaceutical
Unit: 10 mL vial (300 mg/mL)
Prime Constituent: Trenbolone Enanthate
Producer: Dragon Pharma LLC
Package: 10 x 10 mL vial (200 mg/mL)
Main Component: Nandrolone Phenylpropionate
Manufacturer: Dragon Pharmaceuticals
Unit: 10 x 10 mL vial (150 mg/mL)
Basic Ingredient: Tamoxifen Citrate
Made by: Dragon Pharmaceutical
Amount: 100 tabs (20 mg/tab)